There is limited data to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. mAb treatment therapy should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus. There is no available data on the presence of casirivimab and/or imdevimab in human milk or animal milk, the effects on the breastfed infant, or the effects of the drug on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for mAb therapy and any potential adverse effects on the breastfed child from mAb therapy or from the underlying maternal condition.

Leave a Comment